Vitronectin receptor antagonists

A compound according to formula (II):

• 29
• wherein:
• R1 is R7, or A-C0-4alkyl, A-C2-4alkenyl, A-C2-4alkynyl, A-C3-4oxoalkenyl, A-C3-4oxoalkynyl, A-C1-4aminoalkyl, A-C3-4aminoalkenyl, A-C3-4aminoalkynyl, optionally substituted by any accessible combination of one or more of R10 or R7;
• A is H, C3-6cycloalkyl, Het or Ar;
• R7 is —COR8, —COCR′2R9, —C(S)R8, —S(O)mOR′, —S(O)mNR′R″, —PO(OR′), —PO(OR′)2, —NO2, or tetrazolyl;
• each Rg independently is —OR′, —NR′R″, —NR′SO2R′, —NR′OR′, or —OCR′2CO(O)R′;
• R9 is —OR′, —CN, —S(O)rR′, —S(O)mNR′2, —C(O)R′, C(O)NR′2, or —CO2R′;
• R10 is H, halo, —OR11, —CN, —NR′R11, —NO2, —CF3, CF3S(O)r—, —CO2R′, —CONR′2, A-C0-6alkyl-, A-C1-6oxoalkyl-, A-C2-6alkenyl-, A-C2-6alkynyl-, A-C0-6alkyloxy-, A-C0-6alkylamino- or A-C0-6alkyl-S(O)r—;
• R11 is R′, —C(O)R′, —C(O)NR′2, —C(O)OR′, —S(O)mR′, or —S(O)mNR′2;
• 30
• W is —(CHRg)a—U—(CHRg)b—;
• U is absent or CO, CRg2, C(═CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2 N═N, NRgNRg, NRgCRg2, CRg2NRg, CRg2O, OCRg2, C≡C or CRg═CRg;
• G is NRe, S or O;
• Rg is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar—C0-6alkyl;
• Rk is Rg, —C(O)Rg, or —C(O)ORf;
• Ri is is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar—C0-6alkyl, or C1-6alkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2;
• Rf is H, C1-6alkyl or Ar—C0-6alkyl;
• Re is H, C1-6alkyl, Ar—C0-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, or (CH2)kCO2Rg;
• Rb and Rc are independently selected from H, C1-6alkyl, Ar—C0-6alkyl, Het-C0-6alkyl, or C3-6cycloalkyl-C0-6alkyl, halogen, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, or Rb and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, C1-4alkyl, ORf, S(O)kRf, CORf, CO2Rf, OH, NO2, N(Rf)2, CO(NRf)2, and CH2N(Rf)2;
• or methylenedioxy;
• Q1, Q2, Q3 and Q4 are independently N or C—Ry, provided that no more than one of Q1, Q2, Q3 and Q4 is N;
• R′ is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl;
• R″ is R′, —C(O)R′ or —C(O)OR′;
• R′″ is H, C1-6alkyl, Ar—C0-6alkyl, Het-C0-6alkyl, or C3-6cycloalkyl-C0-6alkyl, halogen, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2;
• Ry is H, halo, —ORg, —SRg, —CN, —NRgRk, —NO2, —CF3, CF3S(O)r—, —CO2Rg, —CORg or —CONRg2, or C1-6alkyl optionally substituted by halo, —ORg, —SRg, —CN, —NRgR″, —NO2, —CF3, R′S(O)r—, —CO2Rg, —CORg or —CONRg2;
• a is 0, 1 or 2;
• b is 0, 1 or 2;
• k is 0, 1 or 2;
• m is 1 or 2;
• r is 0, 1 or 2;
• s is 0, 1 or 2;
• u is 0 or 1;
• and
• v is 0 or 1;
• or a pharmaceutically acceptable salt thereof.

A compound according to formula (III):

• 31
• R1 is R7, or A-C0-4alkyl, A-C2-4alkenyl, A-C2-4alkynyl, A-C3-4oxoalkenyl, A-C3-4oxoalkynyl, A-C1-4aminoalkyl, A-C3-4aminoalkenyl, A-C3-4aminoalkynyl, optionally substituted by any accessible combination of one or more of R10 or R7;
• A is H, C3-6cycloalkyl, Het or Ar;
• R7 is —COR8, —COCR′2R9, —C(S)R8, —S(O)mOR′, —S(O)mNR′R″, —PO(OR′), —PO(OR′)2, —NO2, or tetrazolyl;
• each R8 independently is —OR′, —NR′R″, —NR′SO2R′, —NR′OR′, or —OCR12CO(O)R′;
• R9 is —OR′, —CN, —S(O)rR′, —S(O)mNR′2, —C(O)R′, C(O)NR′2, or —CO2R′;
• R10 is H, halo, —OR11, —CN, —NR′R11, —NO2, —CF3, CF3S(O)r, —CO2R′, —CONR′2, A-C0-6alkyl-, A-C1-6oxoalkyl-, A-C2-6alkenyl-, A-C2-6alkynyl-, A-C0-6alkyloxy-, A-C0-6alkylamino- or A-C0-6alkyl-S(O)r—;
• R11 is R′, —C(O)R′, —C(O)NR′2, —C(O)OR′, —S(O)mR′, or —S(O)mNR′2;
• W is —(CHRg)a—U—(CHRg)b—;
• U is absent or CO, CRg2, C(═CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2 N═N, NRgNRg, NRgCRg2, CRg2NRg, CRg2O, OCRg2, C≡C or CRg=CRg;
• Rg is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar—C0-6alkyl;
• Rk is Rg, —C(O)Rg, or —C(O)ORf;
• Ri is is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar—C0-6alkyl, or C1-6alkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2;
• Rf is H, C1-6alkyl or Ar—C6alkyl;
• Q1, Q2, Q3 and Q4 are independently N or C—Ry, provided that no more than one of Q1, Q2, Q3 and Q4 is N;
• R′ is H, C1-6alkyl, Ar—C0-6alkyl or C3-6cycloalkyl-C0-6alkyl;
• R″ is R′, —C(O)R′ or —C(O)OR′;
• Ry is H, halo, —ORg, —SRg, —CN, —NRgRk, —NO2, —CF3, CF3S(O)r—, —CO2Rg, —CORg or —CONRg2, or C1-6alkyl optionally substituted by halo, —ORg, —SRg, —CN, —NRgR″, —NO2, —CF3, R′S(O)r—, —CO2Rg, —CORg or —CONRg2;
• a is 0, 1 or 2;
• b is 0, 1 or 2:
• m is 1 or 2;
• and
• r is 0, 1 or 2;
• or a pharmaceutically acceptable salt thereof.